Navigation Links
Omthera Announces Waiver of Lock-Up Restriction
Date:7/11/2013

mpleted pharmacokinetic and Phase III clinical studies to investigate the safety and efficacy profile of Epanova™. In 2012 the Company reported positive results from its Phase III EVOLVE and ESPRIT trials, both of which were conducted under SPA agreements with the U.S. Food and Drug Administration. Omthera holds worldwide rights to Epanova™ under a license from Chrysalis Pharma AG, a privately held Swiss company that is the owner of the product. For more information, please visit http://www.omthera.com.

Important Information and Where to Find It

On June 13, 2013, the Company filed with the Securities and Exchange Commission (the "SEC") a definitive proxy statement in connection with the proposed transaction (the "Definitive Proxy Statement") and, on June 14, 2013, the Company commenced mailing of the Definitive Proxy Statement to its stockholders.  INVESTORS AND THE COMPANY'S STOCKHOLDERS ARE URGED TO READ THE DEFINITIVE PROXY STATEMENT AND ANY OTHER RELEVANT DOCUMENTS FILED WITH THE SEC WHEN THEY BECOME AVAILABLE BECAUSE THEY CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTION AND THE COMPANY.  Investors and stockholders may obtain free copies of the Definitive Proxy Statement and other documents (when available) that the Company files with the SEC at the SEC's website at http://www.sec.gov.  In addition, the Definitive Proxy Statement and other documents filed by the Company with the SEC may be obtained from the Company free of charge by directing a request to Omthera Pharmaceuticals, Inc., Attn: Christian S. Schade, Executive Vice President and Chief Financial Officer, 707 State Road, Princeton, New Jersey 08540.

Certain Information Concerning Participants

The Company and its directors and executive officers and certain other persons may be deemed to be partici
'/>"/>

SOURCE Omthera Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Omthera Pharmaceuticals Announces Record Date and Meeting Date for Special Meeting of Stockholders
2. Omthera Pharmaceuticals, Inc. Stockholders Seeking More Money, Information in Buyout Should Contact Deans & Lyons Law Firm
3. Omthera Pharmaceuticals Announces First Quarter 2013 Financial Results
4. Covington Advises Omthera Pharmaceuticals on Merger with AstraZeneca
5. Omthera Pharmaceuticals, Inc. Announces Closing of Initial Public Offering
6. Omthera Pharmaceuticals, Inc. Announces Pricing of Initial Public Offering
7. Omthera Pharmaceuticals Presents Data From Analysis Of EVOLVE Trial Showing That Epanova Lowers ApoC-III, A Key Predictor of Cardiovascular Risk
8. Omthera Pharmaceuticals Announces Invitation to Attend Presentation of the Complete Data Sets from its Phase 3 EVOLVE and ESPRIT Clinical Studies
9. Omthera Pharmaceuticals Announces Positive Top-Line Results from Phase 3 EVOLVE Study
10. CryoLife Announces Release Date and Teleconference Call Details for 2013 Second Quarter Financial Results
11. UM Ventures Announces Collaboration Between UM School Of Medicines Dr. Frank Robb and Fina Biosolutions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2014)... Oramed Pharmaceuticals Inc. (NASDAQCM: ... focused on the development of oral drug delivery ... of Spain has granted ... and Compositions for Oral Administrations of Proteins." ... is a technology pioneer in the field of ...
(Date:8/19/2014)... 19, 2014 Research and Markets has ... Strategic Business Report" report to their offering. ... in US$ Thousands by the following three major Application Areas: ... The report provides separate comprehensive analytics for the US, ... Europe , Asia-Pacific , ...
(Date:8/18/2014)... August 19, 2014 Elbit Imaging ... EMITF ) announced today that Elbit Medical Technologies Ltd. ... in which it holds approximately 86% of the voting ... Ltd., in which Elbit Medical holds approximately 30.8% of ... of Gamida Cell,s shareholders (including Elbit Medical), signed Option ...
Breaking Medicine Technology:Oramed Granted Patent in Spain for Oral Administration of Insulin 2Oramed Granted Patent in Spain for Oral Administration of Insulin 3Global Anti-Adhesion Products - Strategic Business Report 2014 2Elbit Imaging Announces Gamida Cell Signs Option and Investment Agreements with Major Pharmaceutical Company 2Elbit Imaging Announces Gamida Cell Signs Option and Investment Agreements with Major Pharmaceutical Company 3
(Date:8/19/2014)... Merrick, NY (PRWEB) August 19, 2014 In honor ... helping you care for your old furry friend by offering tips ... to rely on their owners more. Because of this, dog owners ... for them. , As dogs age, their needs change. They will ... outside as much as they used to. Because of this, pet ...
(Date:8/19/2014)... Following the completion of a $16 million rooms ... is proud to debut the highly anticipated final phase of ... revamp of all public spaces to match the fresh look ... all-new dining experience at 1823 Kitchen and Bar and an ... introduction of 1823 Kitchen and Bar, Grand Hyatt Tampa Bay ...
(Date:8/19/2014)... cannot smoke during their stay and could use this time ... stay smoke-free after returning home. Now a study published ... a program that increased the proportion of hospitalized smokers who ... The system used interactive voice response technology automated ... three months after smokers left the hospital. , ...
(Date:8/19/2014)... 2014 Warfarin, the longtime standard treatment for ... in the anticoagulant drug marketplace including dabigatran, rivaroxaban, ... adoption of these novel oral anticoagulants (NOACs) into ... of all new anticoagulant prescriptions yet this represents ... published in The American Journal of Medicine ...
(Date:8/19/2014)... York, New York (PRWEB) August 19, 2014 ... U.S. courts, Bernstein Liebhard LLP notes the publication of ... antipsychotic medications may increase the risk of acute kidney ... by The Ottawa Citizen, the study was conducted by ... Ont., and the Institute for Clinical Evaluative Sciences, and ...
Breaking Medicine News(10 mins):Health News:The Puppy Store Helps Pet Owners Care for Aging Dogs 2Health News:Grand Hyatt Tampa Bay Hotel Unveils the Finishing Touches of Its $20 Million Makeover 2Health News:Extended support helps patients stay smoke-free after hospital discharge 2Health News:Novel oral anticoagulant prescriptions soar, but at a high cost 2Health News:Novel oral anticoagulant prescriptions soar, but at a high cost 3Health News:As Risperdal Lawsuits Mount, Bernstein Liebhard LLP Notes New Study Linking Atypical Antipsychotic Medications to Kidney Damage in Elderly Patients 2Health News:As Risperdal Lawsuits Mount, Bernstein Liebhard LLP Notes New Study Linking Atypical Antipsychotic Medications to Kidney Damage in Elderly Patients 3Health News:As Risperdal Lawsuits Mount, Bernstein Liebhard LLP Notes New Study Linking Atypical Antipsychotic Medications to Kidney Damage in Elderly Patients 4
... Grubb & Ellis Healthcare,REIT, Inc. today announced the acquisition ... 5550 South East St., Epler Parke Building B is ... square feet of gross leaseable area., Built in ... offers 196 parking spaces and is accessible by Interstates ...
... Iomai Corporation,(Nasdaq: IOMI ) today announced, ... audit report included in the Company,s Annual,Report on ... Commission on,March 27, 2008 for the fiscal year ... This disclosure is required under NASDAQ,marketplace rules and ...
... ULURU Inc. (Amex:,ULU) today announced that it has scheduled ... results and provide a general business update,on Tuesday, April ... participate in the conference call, please dial (800) 357-0498 ... to ten,minutes prior to the initiation of the teleconference. ...
... Conn., March 28 Darwin,Professional Underwriters, Inc. ... the,resignation of Paul F. Romano, who served ... Thursday, March 27th. Mr. Romano has become,associated ... the,Hartford area., (Logo: http://www.newscom.com/cgi-bin/prnh/20060829/NETU014LOGO ...
... suffers collateral damage from blood sugar disease , , FRIDAY, ... cause of heart disease, stroke, blindness, kidney failure and ... quicker than they normally do with age, a new ... in lung function as they grow older, research published ...
... With the full House and,Senate poised to ... Relief,(PEPFAR) reauthorization bill, a five-year, $50 billion initiative ... address,the critical HIV prevention shortfalls in the bill., ... to anti-retroviral drugs,(ARVs) since PEPFAR was enacted in ...
Cached Medicine News:Health News:Grubb & Ellis Healthcare REIT Acquires Epler Parke Building B in Indianapolis 2Health News:Grubb & Ellis Healthcare REIT Acquires Epler Parke Building B in Indianapolis 3Health News:ULURU Inc. Announces Conference Call to Discuss Financial Results for the First Quarter Ended March 31, 2008 and Provide a Business Update 2Health News:Darwin Announces Departure of Senior Vice President 2Health News:Lung Capacity Declines Faster With Diabetes 2Health News:Lung Capacity Declines Faster With Diabetes 3Health News:Will Congress Do More for HIV Prevention? 2Health News:Will Congress Do More for HIV Prevention? 3Health News:Will Congress Do More for HIV Prevention? 4
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: